Table 2 Correlation of serum levels of IFNy with downstream cytokines and chemokines in the whole study cohort

From: Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial

 

Spearman correlation coefficient

Nominal P value

Adjusted P value*

VEGFC

0.202

0.064

0.54

TNFALPHA

0.189

0.083

0.54

IL-4

−0.187

0.086

0.54

IL-2

−0.146

0.18

0.68

PDGF_BB

0.144

0.19

0.68

IL-15

0.129

0.24

0.68

IL1b_IL1F2

0.126

0.25

0.68

MMP9

0.106

0.33

0.78

ANGIOPIETIN2

−0.082

0.46

0.94

CCL2

0.074

0.50

0.94

CXCL5

0.057

0.60

0.94

PIGF

−0.053

0.63

0.94

FGF

0.038

0.73

0.94

CXCL10

0.038

0.73

0.94

HB

0.089

0.74

0.94

VEGF

0.027

0.81

0.96

IL-6

−0.003

0.97

0.98

IL-17

0.002

0.98

0.98

IL-10

0.003

0.98

0.98

  1. P values are adjusted by Benjamini–Hochberg method.